Fig. 4.

Molecular classification of GBM samples into mesenchymal-like and proneural-like GBM subtypes. (A) Hierarchical clustering of 173 TCGA core GBM samples using 142 differentially expressed cotargeted genes. (B) Evaluation of the survival of 109 GBM patients by tumor subtype and TMZ treatment type. Kaplan–Meier analysis was used. (C) Gene order of 142 genes from the TCGA samples was maintained in the validation data set (n = 260). Kappa agreement analysis was performed to compare these subtypes with TCGA subtypes.